Zobrazeno 1 - 10
of 49
pro vyhledávání: '"anti-erythropoietin antibodies"'
Publikováno v:
Clinical Case Reports, Vol 10, Iss 4, Pp n/a-n/a (2022)
Abstract We describe a case of concomitant erythropoietin allergy and resistance with a possible IgE and IgG‐mediated immune response, in which the local allergic cutaneous symptoms preceded the antibody‐mediated anemia.
Externí odkaz:
https://doaj.org/article/32eef138e024436a805f4604fcc0b2dd
Publikováno v:
Sanamed, Vol 13, Iss 1, Pp 61-68 (2018)
Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in p
Externí odkaz:
https://doaj.org/article/c2daee3bcdd74a87a4bb79e79b305477
Publikováno v:
Journal of Nephropathology, Vol 6, Iss 1, Pp 25-29 (2017)
Background: Anemia is a common complication of chronic renal failure due to reduce erythropoietin production by kidneys. Anemia treated with recombinant human erythropoietin (rHu-EPO). Pure red cell aplasia (PRCA) due to antibody productionagainst rH
Externí odkaz:
https://doaj.org/article/9d1e09454510457caa2ec7ef88dc9b6f
Publikováno v:
Journal of International Medical Research, Vol 49 (2021)
The Journal of International Medical Research
The Journal of International Medical Research
Recombinant human erythropoietin (rHuEPO) has been used worldwide for treatment of renal anaemia due to its good curative effect. However, rHuEPO treatment is associated with a rare but severe complication because of the development of anti-EPO antib
Publikováno v:
Sanamed, Vol 13, Iss 1, Pp 61-68 (2018)
Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in p
Publikováno v:
Journal of Nephropathology
Background: Anemia is a common complication of chronic renal failure due to reduce erythropoietin production by kidneys. Anemia treated with recombinant human erythropoietin (rHu-EPO). Pure red cell aplasia (PRCA) due to antibody productionagainst rH
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yasser Bustanji
Publikováno v:
International Journal of Pharmacological Research, Vol 6, Iss 6 (2016)
The aim of the present study was to evaluate the immunogenicity of a generic product of erythropoietin registered in Jordan, by detecting the presence of anti-recombinant human erythropoietin antibodies in the serum via an ELISA technique. Materials
Publikováno v:
Clinical Kidney Journal
The treatment of renal anaemia in patients with chronic kidney disease (CKD) has always been a challenge. The introduction of erythropoiesis-stimulating agents (ESAs) appeared to be a milestone, enabling physicians to avoid red blood cell transfusion
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.